title: [Results of a risk adapted and functional radioiodine therapy in Graves' disease].
abstract: Aim of this study was to find out, if results of a functional orientated radioiodine therapy in Graves' disease could be optimized using a risk adopted dose concept.
  
  
  METHODS
  351 patients with Graves' disease were treated for the first time between 11/97 and 8/01. The basic dose was 125 Gy, which was increased up to 250 Gy in a cumulative manner depending on clinical parameters (initial thyroid metabolism, thyroid volume, immunoreactivity). Two different methods of dosimetry were used. Occasional thyreostasis was withdrawn two days before the radioiodine test was started. Follow up was done on average 8 +/- 2.4 (4-17.2) months. TSH > or = 0.27 microIU/mL confirmed as a measure of the success.
  
  
  RESULTS
  With improved pretherapeutic dosimetry and a mean target dose of 178 +/- 31 Gy (n=72) therapeutic success occurred in 66.7%, in 51.4% euthyreosis was restalled and in 15.3% of patients hypothyroidism was seen (TSH > 4.20 microIU/mL). With simplified pretherapeutic dosimetry and a mean target dose of 172 +/- 29 Gy (n=279) results were moderately impaired (63.8%, 40.1% and 23.7%). With increasing target dose therapeutic failure increased, as insufficiently adopted risk factors for therapeutic failure turned out the initial thyroid metabolism, the TcTU(s) as the (h)TRAb titer.
  
  
  CONCLUSIONS
  Functional orientated RIT can be optimized by including illness specific characteristics, principal limitations are a high initial thyroid metabolism, a large thyroid volume and a high (h)TRAb-titer.
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Zentrum für Radiologie, Universität Rostock, Gertrudenplatz 1, 18057 Rostock, Deutschland. simone.dunkelmann@med.uni-rostock.de
authors.forename: S
authors.initials: S
authors.lastname: Dunkelmann
authors.forename: V
authors.initials: V
authors.lastname: Neumann
authors.forename: U
authors.initials: U
authors.lastname: Staub
authors.forename: P
authors.initials: P
authors.lastname: Groth
authors.forename: H
authors.initials: H
authors.lastname: Künstner
authors.forename: C
authors.initials: C
authors.lastname: Schümichen
mesh_terms: D006111:Graves Disease / Q000097:blood / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D018570:Risk Assessment; D012307:Risk Factors; D013972:Thyrotropin / Q000097:blood
chemical_list: D007457:Iodine Radioisotopes; D013972:Thyrotropin